An interventional study of Early Elective Ascending Aortic Aneurysm Repair in Ascending Aortic Aneurysm Enlargement and Ascending Aorta Aneurysm, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 32 sites in 4 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment
Health Sciences North Research Institute · Baylor Scott and White Health · Duke Clinical Research Institute, Oxford Diabetes Trials Unit · The Valley Hospital · Beth Israel Deaconess Medical Center · Newfoundland Health Services · University of Iowa · Skane University Hospital · Fondation Hôpital Saint-Joseph
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The ascending aorta carries blood from the heart to the rest of the body. The ascending aorta can become enlarged, and the risk of tearing and rupturing becomes higher with larger aorta. When the ascending aorta tears or ruptures, the risk of death is high even if surgery is done as soon as possible. Traditionally, when the ascending aorta gets above 5.5 cm, surgery is recommended to replace the aorta. However, this threshold is based relatively weak evidence, and sometimes patients with smaller aorta can tear or rupture. On the other hand, surgery carries its own risk as well. Since there are risk of waiting or doing surgery, there is currently no great support for either approach for patients with a smaller aorta. In the TITAN:SvS trial, patients with an ascending aorta between 5.0 to 5.4 cm is randomly assigned by chance to the early surgery group, in which they will undergo replacement of aorta, or the surveillance group, in which they will be closely monitored. The chance of dying or suffer tearing or rupture of aorta between the two groups will be compared. The result of the trial will guide future practice for patients with enlarged ascending aorta.
This is a prospective, multi-centre randomized controlled trial that compares the all-cause mortality, aneurysm-related aortic events, rate of stroke, and quality of life for those patients undergoing early elective ascending aortic surgery to those patients undergoing surveillance. Patients referred for an ascending aortic aneurysm that meets the inclusion criteria will be randomized to the early elective surgery group or the surveillance group. Recruitment will end when the desired sample size is reached, and the patients will be followed for up to 10 years. The primary objective of the trial is to compare the composite outcome of the all-cause mortality and incidence of acute aortic events between surveillance and elective ascending aortic surgery for patients with degenerative or bicuspid valve-related ascending aortic aneurysm over a follow-up period of up to 10 years. The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events compared to the surveillance group. The result of this trial will provide evidence based guidance in the appropriate management of ascending aortic aneurysm based on the size criteria, and establish a large database for future investigations.
All patients referred electively to a participating investigator for the evaluation of their ascending aortic aneurysm will be screened for study eligibility. Patients aged 18- 79 with an asymptomatic ascending aortic aneurysm between 5.0 cm and 5.4 cm in maximal diameter will be eligible for randomization. Patients with ascending aortic aneurysm with a diameter of 4.5 cm - 4.9 cm will be observed with serial CT, and will be considered for enrollment into the trial once the aneurysm reaches 5.0 cm.
When the patient is first assessed in clinic, a pre-randomization evaluation will be completed. Baseline information of the patient, including demographics, past medical history, family history, medications, smoking habits, and the characteristics of the aneurysm, is collected. Measurements including weight, height, heart rate, blood pressure in both arms, are recorded. Basic blood samples, including hemoglobin, white cell count, platelets, electrolytes, creatinine, random blood sugar, HbA1c, and cholesterol profile is taken for analysis. An electrocardiogram (ECG), chest X-ray, and a CT scan from the surgeon's institution is also obtained. SF-36, the quality of life questionnaire, will be completed by the patient. Those patients that are suitable for the trial based on inclusion and exclusion criteria will then be randomized en-site through a computer-generated randomization program.
For the patients randomized to elective surgery group, the surgery is scheduled within 6 months of randomization. In the interim, the patient will be placed on maximal medical therapy for their aneurysm, including beta-blocker, statin, and blood pressure control, and the doses of these medication will be individualized based on each patient's own physiological response. The types of surgery (ascending aortic replacement, Bentall procedure, valve-sparing root replacement, etc.) will be at the discretion of the surgeon. The details of the surgery and the patient's course of postoperative hospital stay is recorded. The patient will be managed postoperatively according to routine hospital care. After discharge, patients will be seen at 1 month for their routine postoperative follow up, then annually counting from their index clinic visit before the surgery. At the first postoperative clinic visit, weight, height, heart rate, blood pressure in both arms, is recorded. Basic blood work, including hemoglobin, white cell count, platelets, electrolytes, creatinine is taken for analysis. An electrocardiograph and chest X-ray will be obtained. All subsequent clinic visits can be done in person or by phone conducted by a study coordinator. A CT scan will be obtained at all subsequent clinic visits. Mortality status and occurrence of acute aortic event or stroke in the previous year will be assessed at every annual clinic visit. Quality of life assessment by SF-36 questionnaire will be completed by the patient in person or by phone at 1 year and 3 years follow-up. Annual follow-up will continue until either the patient dies or the trial ends. Patients who are randomized to the surveillance group will be placed on maximal medical therapy for their aneurysm, including beta-blocker, statin, and blood pressure control. The doses of these medication will be individualized based on each patient's own physiological response. The patients will undergo a CT scan of the chest at the first clinic visit then annually for the duration of the study. All CTs will be uploaded to a core CT imaging lab where the image will be reviewed by a Radiologist. If the aneurysm grows beyond 5.5 cm or the patient develop symptoms, the surgeon will consider the patient for surgery. At all clinic visits, in addition to CT, weight, height, heart rate, blood pressure in both arms, an electrocardiograph, and a chest X-ray will be obtained. The surveillance visits continue until either the patient dies, the trial ends, or surgery is considered. If the patient is no longer considered a suitable candidate for surgery or refuse surgery, follow-up will continue, and the patient will no longer be a part of the trial and will only be registered in the side arm.
TITAN:ARCHITECT Registry - Optional Sub-study Eligible participants may be invited to participate in the optional TITAN:ARCHITECT Registry sub-study: Treatment in Thoracic Aortic aNeurysm: ARCH Innovations in TEChniques \& Treatment. This sub-study is an ambispective, multi-centre registry of patients with medically and surgically managed aortic arch pathology. The sub-study includes two groups: an operative registry and a surveillance registry. The operative registry includes patients undergoing eligible aortic arch interventions, while the surveillance registry includes patients with eligible aortic arch pathology who are managed without intervention and followed clinically. Participation in this sub-study is voluntary and will not affect participation in the main TITAN:SvS registry or the participant's clinical care. The sub-study will include collection of additional clinical, operative, imaging, follow-up, re-intervention, survival, and quality-of-life data.
22 studies on the registry are indexed under Aneurysm, Ascending Aorta; 11 are open to participants now.
This study's planned enrollment of 610 is above the median of 164 across 12 interventional studies indexed under Aneurysm, Ascending Aorta.
Browse Aneurysm, Ascending Aorta studies →Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who, in the opinion of the investigator, are deemed unfit for surgery for reasons that may include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the surveillance group will receive medical management for their ascending aortic aneurysm, including blood pressure control and other medications as determined by the attending physician. Patients will undergo annual contrast-enhanced CT scans of the chest to monitor aneurysm progression and will be followed for up to 10 years. If the aneurysm reaches or exceeds 5.5 cm or the patient develops symptoms, surgical intervention will be considered. Patients who undergo surgery will continue to be followed according to the surgical group protocol.
Patients randomized to the early elective surgery group will undergo ascending aortic aneurysm repair within 6 months of randomization. The type of surgical procedure will be determined by the treating surgeon. Patients will receive optimal medical therapy before surgery and routine postoperative care. A CT scan will be obtained approximately 1 year after surgery, with additional imaging as clinically indicated. Patients will be followed annually for up to 10 years to assess mortality, acute aortic events, stroke, and other study outcomes.
Procedure: Early Elective Ascending Aortic Aneurysm Repair
Patients randomized to the early elective surgery group will undergo surgical repair of the ascending aortic aneurysm within 6 months of randomization. The surgical procedure may include ascending aortic replacement, Bentall procedure, or valve-sparing aortic root replacement, with or without concomitant cardiac procedures, as determined by the treating surgeon. Patients will receive optimal medical therapy before surgery and routine postoperative care according to institutional standards.
Composite of All-Cause Mortality and Acute Aortic Events
The primary outcome is a composite of all-cause mortality and acute aortic events in patients randomized to early elective ascending aortic surgery versus surveillance. Acute aortic events include aortic dissection, aortic rupture, intramural hematoma, and penetrating aortic ulcer, regardless of whether death occurs. The primary analysis will be performed once 30 primary outcome events have accrued.
Time frame: From randomization through up to 10 years of follow-up.
Intraoperative Mortality Following Ascending Aortic Aneurysm Repair
Number and proportion of patients who die in the operating room during the ascending aortic aneurysm repair procedure.
Time frame: During the surgical procedure.
Incidence of need for elective ascending aortic aneurysm repair in the surveillance group
How many patients on the surveillance arm of the trial need to have surgery prior to the end of trial surveillance
Time frame: From randomization through up to 10 years of follow-up.
Non aneurysm related death
How many patients in either surgical or surveillance arm have a non aneurysm related death
Time frame: From randomization through up to 10 years of follow-up.
Aneurysm related death
How many patients in either the surveillance or surgical arm have an aneurysm related death
Time frame: From randomization through up to 10 years of follow-up.
Incidence of cerebrovascular accidents (CVA)
How many patients have a CVA on the surgical or surveillance arm
Time frame: From randomization through up to 10 years of follow-up.
Annual growth rate in diameter of ascending aortic aneurysm in the surveillance group
Prospective assessment of the rate of growth in mm/year of moderate sized ascending aortic aneurysms
Time frame: From randomization through up to 10 years of follow-up.
Health-Related Quality of Life
Patients will fill in questionnaires to assess impact of surveillance strategy versus surgery on quality of life
Time frame: From randomization through up to 10 years of follow-up.
All-Cause Mortality Within 30 Days of Ascending Aortic Aneurysm Repair
Number and proportion of patients who die from any cause within 30 days following the ascending aortic aneurysm repair procedure.
Time frame: Within 30 days after the operation.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Sep 2018 (actual). Primary completion is estimated for May 2035, 200 months after the start.
How these figures are worked out, and which studies are left out of them.
Health Sciences North Research Institute · Baylor Scott and White Health · Duke Clinical Research Institute, Oxford Diabetes Trials Unit · The Valley Hospital · Beth Israel Deaconess Medical Center · Newfoundland Health Services · University of Iowa · Skane University Hospital · Fondation Hôpital Saint-Joseph
Health Sciences North Research Institute · Baylor Scott and White Health · Duke Clinical Research Institute, Oxford Diabetes Trials Unit · The Valley Hospital · Beth Israel Deaconess Medical Center · Newfoundland Health Services · University of Iowa · Skang University Hospital
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Heart Institute Research Corporation →